[go: up one dir, main page]

RU2001113688A - APPLICATION OF PACLITAXEL STABILIZED BY ALBUMINE FOR THE PRODUCTION OF A MEDICINE FOR TREATMENT OF SOLID TUMORS AND A MEDICINAL PRODUCED IN THE APPROVED METHOD - Google Patents

APPLICATION OF PACLITAXEL STABILIZED BY ALBUMINE FOR THE PRODUCTION OF A MEDICINE FOR TREATMENT OF SOLID TUMORS AND A MEDICINAL PRODUCED IN THE APPROVED METHOD

Info

Publication number
RU2001113688A
RU2001113688A RU2001113688/14A RU2001113688A RU2001113688A RU 2001113688 A RU2001113688 A RU 2001113688A RU 2001113688/14 A RU2001113688/14 A RU 2001113688/14A RU 2001113688 A RU2001113688 A RU 2001113688A RU 2001113688 A RU2001113688 A RU 2001113688A
Authority
RU
Russia
Prior art keywords
microparticles
solid tumors
medicine
treatment
paclitaxel
Prior art date
Application number
RU2001113688/14A
Other languages
Russian (ru)
Other versions
RU2270003C2 (en
Inventor
Марко ФАЛЬЧЬЯНИ
Original Assignee
Акс Добфар С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2000MI001107A external-priority patent/ITMI20001107A1/en
Application filed by Акс Добфар С.П.А. filed Critical Акс Добфар С.П.А.
Publication of RU2001113688A publication Critical patent/RU2001113688A/en
Application granted granted Critical
Publication of RU2270003C2 publication Critical patent/RU2270003C2/en

Links

Claims (4)

1. Применение микрочастиц паклитаксела, стабилизированных альбумином, для изготовления лекарственного средства для лечения солидных опухолей, чувствительных к паклитакселу, в частности, плоскоклеточных карцином; указанное лекарственное средство включает дисперсию указанных микрочастиц в физиологическом растворе, в котором микрочастицы находятся в концентрации от 2 до 8 мг/мл указанного раствора.1. The use of albumin stabilized paclitaxel microparticles for the manufacture of a medicament for the treatment of solid tumors sensitive to paclitaxel, in particular squamous cell carcinomas; the specified drug includes a dispersion of these microparticles in physiological saline, in which the microparticles are in a concentration of from 2 to 8 mg / ml of the specified solution. 2. Применение микрочастиц по п. 1, отличающееся тем, что концентрация указанных микрочастиц в дисперсии составляет от 3 до 7,5 мг/мл физиологического раствора. 2. The use of microparticles according to claim 1, characterized in that the concentration of these microparticles in the dispersion is from 3 to 7.5 mg / ml of physiological saline. 3. Лекарственное средство для лечения солидных опухолей, чувствительных к паклитакселу, отличающееся тем, что оно включает дисперсию микрочастиц паклитаксела, стабилизированных альбумином, в физиологическом растворе, в котором концентрация микрочастиц составляет от 2 до 8 мг/мл указанного раствора. 3. A medicine for treating solid tumors sensitive to paclitaxel, characterized in that it comprises a dispersion of albumin-stabilized paclitaxel microparticles in physiological saline in which the microparticle concentration is from 2 to 8 mg / ml of said solution. 4. Лекарственное средство по п. 3, отличающееся тем, что концентрация микрочастиц составляет от 3 до 7,5 мг/мл раствора. 4. The drug according to p. 3, characterized in that the concentration of microparticles is from 3 to 7.5 mg / ml of solution.
RU2001113688/15A 2000-05-18 2001-05-17 Paclitaxel-base medicinal agent stabilized with albumin for treatment of solid tumor RU2270003C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (en) 2000-05-18 2000-05-18 METHOD FOR TREATMENT OF SOLIC TUMORS BY INCORPORATING PACLITAXEL MICROPARTICLES OF ALBUMIN
ITMI2000A001107 2000-05-18

Publications (2)

Publication Number Publication Date
RU2001113688A true RU2001113688A (en) 2003-03-10
RU2270003C2 RU2270003C2 (en) 2006-02-20

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001113688/15A RU2270003C2 (en) 2000-05-18 2001-05-17 Paclitaxel-base medicinal agent stabilized with albumin for treatment of solid tumor

Country Status (22)

Country Link
US (1) US6652884B2 (en)
EP (1) EP1155692B1 (en)
JP (1) JP2001354559A (en)
KR (2) KR20010105248A (en)
CN (1) CN1198609C (en)
AT (1) ATE267594T1 (en)
AU (1) AU781517B2 (en)
BR (1) BR0102040A (en)
CA (1) CA2345482A1 (en)
DE (1) DE60103453T2 (en)
DK (1) DK1155692T3 (en)
ES (1) ES2221874T3 (en)
HU (1) HU229909B1 (en)
IL (1) IL142674A0 (en)
IT (1) ITMI20001107A1 (en)
MX (1) MXPA01004980A (en)
NO (1) NO330511B1 (en)
NZ (1) NZ511201A (en)
PT (1) PT1155692E (en)
RU (1) RU2270003C2 (en)
TR (1) TR200101353A2 (en)
ZA (1) ZA200103755B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2433818C2 (en) * 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Compositions, including poorly soluble in water pharmaceutic substances and antimicrobial substances

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING
ITMI20020681A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa PROCEDURE FOR THE PRODUCTION OF PACLITAXEL AND ALBUMINA NANOPARTICLES
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CN1925874B (en) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 Compositions and methods of delivering agents
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR101976003B1 (en) * 2005-02-18 2019-05-09 아브락시스 바이오사이언스, 엘엘씨 Combinations and modes of administration of therapeutic agents and combination therapy
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
AU2006324872B2 (en) * 2005-10-21 2012-03-08 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
ES2700074T3 (en) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Therapy for breast cancer based on the status of the hormone receptors with nanoparticles that comprise taxane
EP2481409B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (en) * 2008-12-30 2011-12-06 최은아 Composition for preventing and treating cancer, including ovary
CA2758913A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion free nanoparticle compositions and methods of making thereof
LT2552438T (en) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Methods of treatment of hepatocellular carcinoma
KR20190109593A (en) 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 Methods of enhancing drug delivery and effectiveness of therapeutic agents
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
MY162903A (en) 2010-06-04 2017-07-31 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
HUE045661T2 (en) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
WO2014143613A1 (en) * 2013-03-13 2014-09-18 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
US9962373B2 (en) 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN116473964A (en) 2015-06-29 2023-07-25 阿布拉科斯生物科学有限公司 Methods of treating epithelioid cell tumors
JP7198666B2 (en) * 2016-08-26 2023-01-04 哲治 奥野 Microvascular blood flow reducing agent and its use
TWI660728B (en) 2018-02-09 2019-06-01 國立交通大學 Quinazolinamine derivatives and pharmaceutical compositions and uses thereof
RU2020134124A (en) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRODUCTION OF NANOPARTICLES CONTAINING mTOR AND ALBUMIN INHIBITOR
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN120919082A (en) * 2025-10-16 2025-11-11 天津医科大学总医院 GelMA microsphere loaded with protein medicine, preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (en) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS.
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1999000113A1 (en) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP1100494A1 (en) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2433818C2 (en) * 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Compositions, including poorly soluble in water pharmaceutic substances and antimicrobial substances

Similar Documents

Publication Publication Date Title
RU2001113688A (en) APPLICATION OF PACLITAXEL STABILIZED BY ALBUMINE FOR THE PRODUCTION OF A MEDICINE FOR TREATMENT OF SOLID TUMORS AND A MEDICINAL PRODUCED IN THE APPROVED METHOD
HUP0102039A2 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
CY1109861T1 (en) INTERDERATIVE THERAPEUTIC SYSTEM FOR PARKINI DISEASE Causing High Plasma Rotigotine Level
CA2503719A1 (en) Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases
WO2004002445A3 (en) Novel floating dosage form
DE60222383D1 (en) MEDICAMENT FOR THE ADMINISTRATION OF AMIFOSTIN AND RELATED ACTIVE SUBSTANCES
LU82013A1 (en) NOVEL LYOPHILIZED POWDERS CONTAINING THIAZOLIDINE-4-CARBOXYLIC ACID SALT AND PROCESS FOR THEIR PREPARATION
BR0116653A (en) Medicinal product containing a polyamine as active substance
DK0559145T3 (en) Drug for menacing abortion
EA200800075A1 (en) DOSING CIRCUIT FOR WISE
JP2004521140A5 (en)
CY1105545T1 (en) STATIN THERAPY TO ENHANCE THE PRESERVATION OF MENTAL FUNCTION
RU2002105074A (en) METHOD FOR TREATING AND PREVENTING THE DEVELOPMENT OF HYPERTROPHIC AND KELOID SCARS
RU97104062A (en) APPLICATION OF SELEGYLIN FOR TREATMENT OF EPILEPTIC DISEASES
RU2002104753A (en) Method for the prevention and treatment of cattle leukemia
DE60018759D1 (en) ANTI-ISCHEMIC ACTIVE
RU2000126186A (en) A method for the treatment of anterior uveitis
WO2003082342A1 (en) Application of kiaa0172 gene to treatment and diagnosis of diseases and drug discovery
RU2000118509A (en) A method for the treatment of neovasculogenesis after end-to-end keratoplasty
RU2002134891A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF GENITAL ACUTE-FINAL CONDILOMATOSIS
RU2001113054A (en) A method for the treatment of postpartum acute purulent-catarrhal endometritis of cows
RU2001132588A (en) New Use of Substances for PMS
RU2003106097A (en) METHOD FOR THE CONTROLLED REDUCTION OF THE AGGREGATION ACTIVITY OF THROMBOCYTES IN THE EXPERIMENT
Nicholson Ask the doctor. In your article on Alzheimer's disease (March, 1999), you mention" high doses of vitamin E" as helpful in slowing the progression of the condition. Specifically, what dose is recommended?
TH61968A (en) Mertazapine for the treatment of sleep disorders